Chinese biopharma known for icotinib (Conmana), China's first domestically developed targeted lung-cancer (EGFR inhibitor) drug.
Chinese biopharma known for icotinib (Conmana), China's first domestically developed targeted lung-cancer (EGFR inhibitor) drug.
Most sales come from icotinib, sold to hospitals through distributors and reimbursed through China's state insurance list, so price negotiations, patent life and competing EGFR drugs decide the pace. Further cancer drugs are being added to reduce dependence on that single product.
Moat: narrow (IP / patents, regulatory licence). Patent-protected, first-to-market domestic EGFR-inhibitor franchise.
Headquarters: Hangzhou, China · Employees: 1,785
Size Betta Pharmaceuticals (300558.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $2.70B, the 877th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥42.81 on 18 Nov 2026.
Performance Over six months the shares fell 15.3%, against -9.7% for the median peer and -20.0% for the China market (cap-weighted) — 7th lowest of 21 in its peer set.
Growth Revenue grew 16.5% over the last twelve months (peer median +2.6%); the operating margin is 11.3% (peer median 9.3%).
Valuation It trades at 38.0× forward earnings against a peer median of 24.2× (6th most expensive of 17).
Price implies For today's price to make sense, revenue must grow about 23% a year for seven years (Req g). Recent delivered growth is +14%, so the hurdle is +9 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 3.6 points below its cost of capital (11.2% WACC).
Next results Next results expected around 28 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥3.80B | CN¥3.60B | CN¥2.88B | CN¥2.45B | CN¥2.36B |
| Revenue growth | — | +25% | +18% | +4% | — |
| Gross profit | CN¥3.12B | CN¥2.56B | CN¥2.17B | CN¥1.88B | CN¥1.94B |
| EBITDA | n/a | CN¥1.09B | CN¥848M | CN¥583M | CN¥412M |
| Net income | CN¥267M | CN¥305M | CN¥403M | CN¥348M | CN¥145M |
| Free cash flow | CN¥312M | CN¥296M | CN¥83.6M | -CN¥182M | -CN¥704M |
| Capital expenditure | CN¥550M | CN¥617M | CN¥828M | CN¥1.10B | CN¥1.01B |
| Total debt | CN¥2.47B | CN¥2.50B | CN¥2.39B | CN¥2.43B | CN¥1.76B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Betta Pharmaceuticals 300558.SZ | $2.70B | -15% | +16% | 11% | 38.0× | 23.2% |
| AstraZeneca AZN.L | $278B | -2% | +5% | 23% | 17.6× | 14.4% |
| Jiangsu Hengrui Pharmaceuticals 600276.SS | $45.7B | -13% | +6% | 27% | 33.4× | 13.4% |
| Hansoh Pharma 3692.HK | $25.3B | -3% | +25% | 38% | 25.8× | 7.9% |
| Shanghai Allist Pharmaceuticals 688578.SS | $5.32B | -14% | +39% | 47% | 12.4× | 0.1% |
| Roche RO.SW | $381B | +21% | -1% | 31% | 19.9× | 1.7% |
| Innovent Biologics 1801.HK | $18.9B | +4% | +43% | 17% | 52.3× | 11.6% |
| Sbp 1177.HK | $12.2B | +5% | +15% | 30% | 17.5× | -5.7% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 300558.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +2.3% | -6.7% | 7th highest of 21 |
| 6-month return | -15.3% | -9.7% | 7th lowest of 21 |
| Distance from 52-week high | -45.2% | -33.4% | 5th lowest of 21 |
| Revenue growth (TTM) | +16.5% | +2.6% | 8th highest of 21 |
| Operating margin | 11.3% | 9.3% | 10th highest of 21 |
| Forward P/E | 38.0× | 24.2× | 6th most expensive of 17 |
| Growth the price implies (Req g, 7 yrs) | 23.2% | 11.7% | 6th most demanding of 15 |
| Growth delivered (Del g) | +14.0% | +6.8% | 7th highest of 15 |
| Hurdle (Req g minus delivered) | +9.2 pp | -1.0 pp | 6th most demanding of 15 |
| ROIC minus cost of capital | -3.6 pp | +0.1 pp | 6th lowest of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Betta Pharmaceuticals 300558.SZ | China | $2.70B | -15% | +16% | 11% | 38.0× | 23.2% | +14.0% |
| Hybio Pharmaceutical 300199.SZ | China | $2.68B | -8% | +70% | 31% | 44.7× | 37.4% | +6.1% |
| BioArctic BIOA-B.ST | Sweden | $2.66B | -9% | -46% | 22% | 52.9× | 25.5% | +100.1% |
| Kangmei Pharmaceutical 600518.SS | China | $2.61B | -21% | -6% | -7% | n/a | n/a | n/a |
| IDEAYA Biosciences IDYA | United States | $2.56B | -11% | -83% | -1,267% | n/a | n/a | n/a |
| Joincare Pharmaceutical Group Industry 600380.SS | China | $2.85B | 0% | -12% | 18% | 15.5× | -13.1% | +2.4% |
| Yili Chuanning Biotechnology 301301.SZ | China | $2.49B | -24% | -14% | 16% | 27.6× | 3.4% | +4.8% |
| Neuland Laboratories NEULANDLAB.NS | India | $2.95B | +28% | +50% | 26% | 63.4× | n/a | n/a |
| China Medical System 0867.HK | Hong Kong | $2.95B | -15% | +15% | 20% | 9.8× | 1.1% | +2.7% |
| Almirall ALM.MC | Spain | $2.46B | -13% | +24% | 8% | 27.1× | 6.1% | +6.5% |
| Chengdu Kanghong Pharmaceutical 002773.SZ | China | $2.99B | -1% | -11% | 24% | 20.1× | -3.3% | +7.0% |
| Vericel VCEL | United States | $2.99B | +66% | +25% | 8% | 68.3× | 46.5% | +17.3% |
| Prestige Consumer Healthcare PBH | United States | $2.40B | +7% | +5% | 25% | 10.6× | 2.3% | +2.9% |
| InSilico Medicine Cayman TopCo 3696.HK | Hong Kong | $2.40B | -33% | +153% | -7% | 85.2× | 37.9% | +22.9% |
| Keymed Biosciences 2162.HK | Hong Kong | $2.39B | +7% | 0% | -73% | 18.2× | n/a | n/a |
| Shanghai Henlius Biotech 2696.HK | Hong Kong | $3.05B | -39% | +33% | 12% | 21.3× | 14.1% | +61.4% |
| HUTCHMED (China) 0013.HK | Hong Kong | $2.38B | +14% | -9% | -6% | 35.9× | 47.0% | +19.3% |
| ACADIA Pharmaceuticals ACAD | United States | $3.08B | -15% | +15% | 10% | 17.8× | 9.2% | +19.4% |
| NewAmsterdam Pharma NAMS | United States | $2.37B | -45% | -26% | -900% | n/a | n/a | n/a |
| Sam Chun Dang Pharm 000250.KS | South Korea | $2.36B | -66% | +23% | 7% | n/a | n/a | n/a |
| Perrigo PRGO | United States | $2.35B | +52% | -4% | 5% | 6.7× | 14.1% | +0.8% |